NCT06554587 Investigation of Three Biomarkers for the Detection of Prostate Cancer
| NCT ID | NCT06554587 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medtechtomarket Consulting Ltd |
| Condition | Cancer of Prostate |
| Study Type | OBSERVATIONAL |
| Enrollment | 137 participants |
| Start Date | 2025-01-07 |
| Primary Completion | 2026-01-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 137 participants in total. It began in 2025-01-07 with a primary completion date of 2026-01-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test. This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.
Eligibility Criteria
Inclusion Criteria: * Male patients aged 18 years and over * The patient is being investigated for suspected prostate cancer or is on active surveillance * The patient is able to give consent to take part in the study Exclusion Criteria: * A patient who has already taken part in the study * A patient with an active urinary tract infection * The patient has a prior diagnosis of any other cancer or is receiving any cancer treatment (including ADT) * The patient is currently or within the last 4 months enrolled on another study involving an investigational medicinal product
Contact & Investigator
Henry P Lazarowicz, FRCS(Urol)
PRINCIPAL INVESTIGATOR
Liverpool University Hospitals NHS Foundation Trust
Frequently Asked Questions
Who can join the NCT06554587 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Cancer of Prostate. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06554587 currently recruiting?
Yes, NCT06554587 is actively recruiting participants. Contact the research team at rebecca.newman@medtechtomarket.com for enrollment information.
Where is the NCT06554587 trial being conducted?
This trial is being conducted at Liverpool, United Kingdom.
Who is sponsoring the NCT06554587 clinical trial?
NCT06554587 is sponsored by Medtechtomarket Consulting Ltd. The principal investigator is Henry P Lazarowicz, FRCS(Urol) at Liverpool University Hospitals NHS Foundation Trust. The trial plans to enroll 137 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.